Pancreatic Cancer Research

ResearcherOregon Health & Science UniversityActive in the last 2 years

Katelyn T. Byrne

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2459-9041; OpenAlex author ID A5023887178. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 4 papers

Papers 13

  1. Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for clinical trial design. Co-author DOI 10.1016/j.canlet.2026.218864↗
  2. Interleukin 6 Drives Durable T Cell-Mediated Immunity to Pancreatic Cancer. Co-author DOI 10.1016/j.jcmgh.2026.101768↗
  3. Opening the window for immunotherapy in pancreatic cancer. First author DOI 10.1158/0008-5472.can-26-4570↗
  4. IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-25-1612↗
  5. Disabling PSGL-1 abrogates immune suppression and resistance to PD-1 blockade in pancreatic cancer Co-author DOI 10.1101/2025.05.22.655365↗
  6. HuR-Regulated Extracellular Vesicles Promote Endothelial Cell Remodeling in Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-25-0355↗
  7. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-23-0873↗
  8. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE… Co-author DOI 10.1038/s41591-022-01829-9↗
  9. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/s1470-2045(20)30532-5↗
  10. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1047↗
  11. Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3791/60497↗
  12. Immunotherapy and Prevention of Pancreatic Cancer. First author DOI 10.1016/j.trecan.2018.04.001↗
  13. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. Co-author DOI 10.1172/jci.insight.88328↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Margaret E. Haerr · 2 shared papers, 2025–2026 · strength 0.85
  2. Rosalie C. Sears · 3 shared papers, 2025–2026 · strength 0.71
  3. Robert H. Vonderheide · 6 shared papers, 2016–2024 · strength 0.65
  4. Aaron J. Grossberg · 2 shared papers, 2026 · strength 0.51
  5. Lisa M. Coussens · 3 shared papers, 2021–2026 · strength 0.50
  6. Kyle P. Gribbin · 2 shared papers, 2026 · strength 0.49
  7. Charles D. Lopez · 2 shared papers, 2026 · strength 0.49
  8. Jennifer M. Finan · 2 shared papers, 2025–2026 · strength 0.48
  9. Jonathan Robert Brody · 2 shared papers, 2025–2026 · strength 0.48
  10. Zheng Xia · 2 shared papers, 2025–2026 · strength 0.45
  11. Canping Chen · 2 shared papers, 2025–2026 · strength 0.45
  12. Katie E. Blise · 2 shared papers, 2024–2026 · strength 0.41
  13. Mark H. O’Hara · 3 shared papers, 2021–2022 · strength 0.28
  14. Andressa Dias Costa · 2 shared papers, 2021–2024 · strength 0.28
  15. Brian Matthew Wolpin · 2 shared papers, 2021–2024 · strength 0.28
  16. Jonathan Andrew Nowak · 2 shared papers, 2021–2024 · strength 0.28
  17. Adel Kardosh · 1 shared paper, 2026 · strength 0.26
  18. Teresa A Zimmers · 1 shared paper, 2026 · strength 0.26
  19. Michael Jon Pishvaian · 1 shared paper, 2026 · strength 0.26
  20. Parham Diba · 1 shared paper, 2026 · strength 0.24
  21. Paige C. Arneson‐Wissink · 1 shared paper, 2026 · strength 0.24
  22. Robert L Eil · 1 shared paper, 2026 · strength 0.24
  23. Gordon Brent Mills · 1 shared paper, 2026 · strength 0.23
  24. Mara H. Sherman · 1 shared paper, 2026 · strength 0.23
  25. Emanuel F. Petricoin · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.